Targeting the IDO1 pathway in cancer: from bench to bedside

• Published in: Journal of hematology and oncology Vol. 11; no. 1; pp. 100 - 12
• Main Authors: Liu, Ming, Wang, Xu, Wang, Lei, Ma, Xiaodong, Gong, Zhaojian, Zhang, Shanshan, Li, Yong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.08.2018; BioMed Central; BMC
• Subjects: 3-dioxygenases; Acids; Adoptive transfer; Antigens; Cancer; Cancer immunotherapy; Cancer therapies; Cancer vaccines; Care and treatment; Chimeric antigen receptors; Clinical trial; Clinical trials; Dioxygenase; Enzymes; Gene expression; Genetic aspects; Genomes; Hematology; IDO1; Immune checkpoint; Immunoglobulins; Immunoregulation; Immunosuppression; Immunosurveillance; Immunotherapy; Indoleamine 2; Kinases; Leukemia; Lymphocytes; Lymphocytes T; Metabolism; Metastasis; Natural killer cells; Oncology; Oxidases; Physiological aspects; Prostate; Review; Solid tumors; Suppressor cells; Tryptophan; Tumor necrosis factor-TNF; Tumors; Vascularization; United States; China; Indoleamine 2; Clinical trial; Immunosuppression; 3-dioxygenases; Immunotherapy; IDO1

Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regu...